Financial Performance - The company's operating revenue for 2023 was ¥2,248,962,053.98, representing a 7.90% increase compared to ¥2,084,250,399.00 in 2022[23]. - Net profit attributable to shareholders for 2023 was ¥452,942,064.27, a 30.64% increase from ¥346,698,684.97 in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥318,420,957.50, up 13.43% from ¥280,715,394.08 in 2022[23]. - The total assets at the end of 2023 reached ¥6,595,941,501.08, an 8.02% increase from ¥6,106,273,672.25 at the end of 2022[23]. - The basic earnings per share for 2023 was ¥0.9772, a 30.50% increase compared to ¥0.7488 in 2022[23]. - The company reported a net cash flow from operating activities of ¥378,196,328.60, a slight decrease of 2.90% from ¥389,486,980.07 in 2022[23]. - The company achieved a revenue of 2.249 billion yuan in 2023, representing a year-on-year growth of 7.90%[88]. - The net profit attributable to the parent company was 453 million yuan, an increase of 30.64% compared to the previous year[88]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 318 million yuan, up 13.43% year-on-year[88]. Market Position and Strategy - The company has a strategic focus on expanding its market presence and enhancing its product development capabilities[4]. - The company aims to strengthen its market position through strategic expansions and potential acquisitions in the veterinary medicine industry[50]. - The company is focusing on the pet health market, with plans to establish itself as a leading domestic brand, leveraging the growing pet population and market potential[73]. - The company is actively pursuing research and development of innovative veterinary products to meet the growing market demand and enhance its competitive edge in the industry[122]. - The company is committed to enhancing its supply chain advantages and improving production processes to reduce costs across all supply chain nodes[153]. - The company intends to deepen its poultry business and increase vaccine sales to further improve market share[153]. - The company is focusing on the pet industry, aiming to become a globally recognized brand by enriching its industry chain layout and building a channel ecosystem[153]. Research and Development - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management team[4]. - The company has a strong R&D team, including 8 national-level talents and 23 provincial-level experts, enhancing its innovation capabilities across various scientific fields[74]. - R&D investment increased from 15.16 million in 2021 (7.55% of revenue) to 23.28 million in 2023 (10.35% of revenue), driving product innovation and market expansion[71]. - The company has developed multiple key technology platforms for drug research, including new drug design and screening, which have led to dozens of innovative inventions in new drug crystal forms and compound structures[80]. - The company has established long-term cooperative relationships with over 30 renowned research institutions, enhancing its innovation capabilities[76]. - The company has made significant advancements in mRNA vaccine development, with multiple products in strategic planning, enhancing its competitive edge in the market[78]. - The company is advancing its IPD R&D system transformation, focusing on product competitiveness and optimizing product launch processes for new products such as cat vaccines and antibiotics[155]. Product Development and Innovation - The company has obtained 15 new veterinary drug registration certificates for pets, including the first domestic cat trivalent vaccine, "Rui Miao Shu," which broke the reliance on imported vaccines[47]. - The company has developed a new generation of high-temperature resistant β-mannanase enzyme, enhancing gut health and nutrient utilization[54]. - The company’s new feed additive enzyme can improve nutrient absorption efficiency and save over 50 kcal/kg of feed energy[54]. - The company has successfully developed the "Porcine Circovirus Type 2 Genetic Engineering Subunit Vaccine," which is the first of its kind for the company and is currently in the new veterinary drug product approval stage[119]. - The company has developed a dual live vaccine for the prevention of Newcastle disease and infectious bronchitis, which can be stored at 2-8°C for up to 24 months, addressing significant challenges in poultry farming[121]. - The company has developed a bivalent yolk antibody for the emergency prevention of duck viral hepatitis, enhancing its therapeutic antibody offerings for waterfowl[121]. - The company has successfully developed a new canine parvovirus serum, which induces endogenous interferon production and promotes antibody formation, filling a gap in the pet product line and addressing market needs[122]. Risks and Challenges - The company faces risks including animal epidemic risks, market competition risks, talent loss risks, and product development risks[4]. - The company is facing risks from animal epidemics, market competition, and potential talent loss, which could impact its operational performance[161][162][164]. - The company emphasizes the importance of a stable R&D team, as high-end talent is crucial for maintaining competitive advantages in the veterinary vaccine market[164]. - The company has implemented a cautious customer credit policy and established a bad debt provision policy based on industry comparisons and historical sales recovery data[167]. Governance and Management - The company maintains an independent business operation, with its board of directors, supervisory board, and internal institutions operating independently from the controlling shareholder[176]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[176]. - The company has established a performance evaluation and incentive system for its directors and senior management, ensuring transparency and compliance with regulations[183]. - The company has strengthened investor relations management and communication to protect the rights of investors, especially minority shareholders[173]. - The company has a structured approach to shareholder meetings, ensuring adequate time for shareholders to express their opinions and separate voting for minority shareholders on significant matters[174]. Awards and Recognition - The company has received multiple awards for its research and development efforts, including two National Science and Technology Progress Awards (second class) and several local awards[196]. - The company has been recognized as a leader in the industry, receiving accolades for its contributions to agricultural biotechnology and veterinary medicine[196]. - The company participated in the 17th China Listed Company Value Evaluation Activity and was recognized as one of the "Top 50 Value Companies on the Growth Enterprise Market"[173].

[盈利预测与财务指标 Table_Forcast] 推荐 维持评级 当前价格： 14.43 元 1.瑞普生物（300119.SZ）2023 年三季报点 评：2023Q3 盈利能力逐步修复，猫三联上市 有序推进-2023/10/26 2.瑞普生物（300119.SZ）事件点评：应急评 价正式通过，公司有望成为猫三联国产化先锋 -2023/08/24 本公司具备证券投资咨询业务资格，请务必阅读最后一页免责声明 证券研究报告 2 瑞普生物（300119.SZ）2023 年年度报告点评 | --- | --- | --- | --- | --- | |----------------------------------------------------|-------|-------------------------|------------|-------| | 项目 /年度 | 2023A | 2024E | 2025E | 2026E | | 营业收入（百万元） | | 2,249 2,752 3,115 3,518 | | | | 增长率（%） | | 7.9 22.4 13.2 13.0 | | | | ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-021 天津瑞普生物技术股份有限公司 关于收购保定市收骏科技有限公司100%股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、天津瑞普生物技术股份有限公司（以下简称"公司"）拟以自有资金或自 筹资金收购保定市收骏科技有限公司（以下简称"保定收骏"、"标的公司"）100% 股权，收购完成后，保定收骏将纳入公司合并报表范围。 2、本次交易构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，不构成重组上市，无需取得有关部门批准。根据《深圳证券 交易所创业板股票上市规则》和《公司章程》的相关规定，本次关联交易尚需提 交公司股东大会审议。 3、受宏观经济波动、行业政策变化和竞争环境加剧等因素影响，保定收骏 未来盈利能力存在不确定性，敬请广大投资者注意投资风险。 一、关联交易概述 （一）交易内容 为补足公司口蹄疫疫苗产品布局，提升向家畜客户提供疫病整体解决方案的 能力，持续增强核心竞争力，公司于 2024 年 3 月 28 日在天津市签署《股权转让 协 ...

中国银河证券股份有限公司 关于天津瑞普生物技术股份有限公司 2021 年向特定对象发行股票 持续督导保荐总结报告书 中国银河证券股份有限公司（以下简称"中国银河证券"或"保荐人"）作 为天津瑞普生物技术股份有限公司（以下简称"瑞普生物"或"公司"）2021 年 度向特定对象发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关法律、法规 和规范性文件的规定，对瑞普生物履行持续督导义务，持续督导期至 2023 年 12 月 31 日止。目前，中国银河证券对瑞普生物 2021 年度向特定对象发行股票并在 创业板上市的持续督导期已满，现出具保荐总结报告书如下： 一、保荐人及保荐代表人承诺 （一）保荐总结报告书及其相关资料的内容不存在虚假记载、误导性陈述或 重大遗漏，保荐人及保荐代表人对其真实性、准确性、完整性承担法律责任。 （二）保荐人及保荐代表人自愿接受中国证券监督管理委员会（以下简称"中 国证监会"）对保荐总结报告书相关事项进行的任何质询和调查。 （三）保荐人及保荐代表人自愿接受中国证监会按照《证券发行上市保荐业 务管理办法》及《深圳证券交易 ...

天津瑞普生物技术股份有限公司 审计报告及财务报表 二○二三年度 信会师报字[2024]第 ZG10531 号 天津瑞普生物技术股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-6 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动 | 9-12 | | | 表 | | | | 财务报表附注 | 1-148 | 审计报告 信会师报字[2024]第 ZG10531 号 天津瑞普生物技术股份有限公司全体股东： 一、 审计意见 我们审计了天津瑞普生物技术股份有限公司（以下简称瑞普生 物）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务 ...

提请股东大会授权董事会以简易程序向特定对象发行股票 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司于2024年3月28日召开第五届董事会第十三 次会议及第五届监事会第十次会议，审议通过了《关于提请股东大会授权董事会 以简易程序向特定对象发行股票的议案》，该议案尚需提交公司2023年年度股东 大会审议。现将具体情况公告如下： 证券代码：300119 证券简称：瑞普生物 公告编号：2024-019 天津瑞普生物技术股份有限公司关于 一、具体内容 根据《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"） 《深圳证券交易所上市公司证券发行上市审核规则》《深圳证券交易所上市公司 证券发行与承销业务实施细则》等相关规定，公司董事会提请股东大会授权董事 会决定向特定对象发行融资总额不超过人民币3亿元且不超过最近一年末净资产 20%的股票，授权期限为2023年年度股东大会通过之日起至2024年年度股东大会 召开之日止。本次授权事宜包括以下内容： 1、确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会根据《中华人民共 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-020 天津瑞普生物技术股份有限公司 关于部分募投项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于2024年3月28日召 开了第五届董事会第十三次会议及第五届监事会第十次会议，审议通过了《关于 部分募投项目延期的议案》，同意公司募集资金投资项目实施主体、实施方式、 募集资金投资用途及投资规模不发生变更的情况下，将"华南生物大规模悬浮培 养车间建设项目"、"研发中心升级改造—生物制品研究院二期项目"达到预定 可使用状态的日期进行调整，现将具体情况公告如下： 一、募集资金基本情况 三、本次部分募投项目延期具体情况 公司结合目前募集资金投资项目的实际进展情况，在项目实施主体、实施方 式、募集资金投资用途及投资规模都不发生变更的情况下，经审慎研究，将"研 发中心升级改造—生物制品研究院二期项目"达到预定可使用状态的日期由2023 年10月31日调整至2024年12月31日，"华南生物大规模悬浮培养车间建设项目" 达到预定可使用状态的日期由2 ...

本报告依据中国资产评估准则编制 天津瑞普生物技术股份有限公司拟进行股权收购 所涉及的保定市收骏科技有限公司 股东全部权益价值项目 资产评估报告 ： 银信评报字（2024）第 A00023号 (共1册第1册) 银信资产评估有限公司 2024年03月26日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 3131020026202400459 | | --- | --- | | 合同编号: | HT2024-A00025 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 银信评报字(2024)第A00023号 | | 报告名称: | 天津瑞普生物技术股份有限公司拟收购股权所涉及 的保定收骏科技有限公司股东全部权益价值项目 | | 评估结论: | 240.024.870.92元 | | 评估报告日: | 2024年03月26日 | | 评估机构名称: | 银信资产评估有限公司 | | 签名人员: | (资产评估师) 会员编号:11220008 成啥 | | | 董秋辰 (资产评估师) 会员编号:11230062 | (可扫描二维码查询备案业务信息) 说明：报告备案回执仅证明此 ...

| 保荐机构名称：中国银河证券股份有限公司 | 被保荐公司简称：瑞普生物 | | --- | --- | | 保荐代表人姓名：王飞 | 联系电话：010-80927009 | | 保荐代表人姓名：郭玉良 | 联系电话：010-80927107 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2.督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | | | | 是 | | 募集资金管理制度、内控制度、内部审计制 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月查询 | | （2）公司募集资金项目进展是否与信息披 | 是 | | 露文件一致 | | | 4.公司治理督导情况 | | | （1）列席公司股东大会次数 | 0 | | ...

中国银河证券股份有限公司 关于天津瑞普生物技术股份有限公司 中国银河证券股份有限公司（以下简称"银河证券"或"保荐机构"）作为天津瑞 普生物技术股份有限公司（以下简称"瑞普生物"）2021 年度向特定对象发行股票的 保荐机构，根据《证券发行上市保荐业务管理办法（2023 修订）》《深圳证券交易所上 市公司自律监管指引第 13 号—保荐业务》《深圳证券交易所创业板股票上市规则（2023 年 8 月修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作（2023 年 12 月修订）》《上市公司监管指引第 2 号—上市公司募集资金管理和 使用的监管要求（2022 年修订）》等相关规定，对公司 2023 年度募集资金存放与使用 情况及专项报告进行了审慎核查，具体核查情况和核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 9 月 10 日下发 的《关于同意天津瑞普生物技术股份有限公司向特定对象发行股票注册的批复》（证监 许可〔2021〕2974 号），同意公司向特定对象发行股票的注册申请。公司向特定 ...